Editorial board

Contact

: Taylor & Francis Executive Editor, [email protected].

Editor-in-Chief

Leslie Citrome, MD, MPH

Clinical Professor of Psychiatry and Behavioral Sciences

New York Medical College

Valhalla, NY, USA

(Dr Citrome has disclosed that he is a consultant for: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, COMPASS, Eisai, Enteris BioPharma, HLS Therapeutics, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Lyndra, Medavante-ProPhase, Merck, Neurocrine, Neurelis, Novartis, Noven, Otsuka, Ovid, Praxis, Relmada, Reviva, Sage, Sunovion, Supernus, Teva, University of Arizona, and also provides one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research. He is also a speaker for: AbbVie/Allergan, Acadia, Alkermes, Angelini, BioXcel, Eisai, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Takeda, Teva, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies. He holds stocks (small number of shares of common stock) in: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer purchased more than10 years ago and stock options: Reviva.
He also receives royalties/publishing from: Wiley (Editor-in-Chief, International Journal of Clinical Practice, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics).

Editor Emeritus

Dimitri P. Mikhailidis, MD, FFPM, FRCP, FRCPath

Reader and Academic Head, Department of Clinical Biochemistry
Royal Free Hospital and University College Medical School
London, UK

Editorial Board

Raid Alany

Chair in Pharmaceutics
School of Pharmacy and Chemistry
Kingston University London
Penrhyn Road
Kingston upon Thames
Surrey KT1 2EE

Prof. Alany has disclosed that he has no relevant financial relationships.

Carl V. Asche

Director, Center for Outcomes Research,

University of IllinoisCollege ofMedicine at Peoria
Peoria, IL, USA

Dr Asche has disclosed that he is the recipient of research/grant funding from Takeda, Abbott and Novartis, and that he is a consultant/advisor to Sanofi-Aventis.

Anthony H. Barnett, MD, FRCP

Professor of Medicine, Honorary Consultant Physician
University of Birmingham Medical School
Birmingham, UK

Prof. Barnett has disclosed that he has received honoraria for lectures and advisory work from MSD, Novartis, Boeheringer-Ingelheim, Astra-Zeneca, Janssen, Eli Lilly, Sanofi-Aventis and Novo Nordisk.

Nicholas Bellamy

Centre of National Research on Disability and Rehabilitation Medicine
The University of Queensland
Brisbane, Australia

Emeritus Prof. Bellamy has disclosed that he is the owner of the WOMAC trademark and copyrights to WOMAC, AUSCAN, 02MS, OGI and WOMBAT health status instruments and PARIS sectogram.

Jonathan Belsey, MD

JB Medical Ltd.
Little Cornard, Sudbury, Suffolk, UK

Dr Belsey has disclosed that he has been a consultant to Avita Medical Ltd, Bayer plc, Daiichi-Sankyo Europe, EUSA Pharma, GlaxoSmithKline, Ipsen Pharma, Janssen EMEA, Janssen UK, Menarini Pharma UK and Norgine Lttd

Kathryn Blake

Biomedical Research Department
Nemours Children’s Speciality Care
Jacksonville, FL, USA

Dr Blake has disclosed that she has no relevant financial relationships.

Christopher M. Blanchette

College of Health and Human Services
University of North Carolina,
Charlotte, NC, USA

Dr Blanchette has disclosed that he is the recipient of research/grant funding from GlaxoSmithKline, AstraZeneca, Merck, Covidien and Boehringer-Ingelheim, and is a consultant/advisor to GlaxoSmithKline, Sepracor, AstraZeneca and Novartis.

Eric G. Boyce

Department of Pharmacy Practice
University of the Pacific
Stockton, CA, USA

Dr Boyce has disclosed that he has no relevant financial relationships.

Olivier Bruyere

Department of Public Health, Epidemiology and Health Economics
Liege University
Liege, Belgium

Prof. Bruyère has disclosed that he has received grant support from Bayer, IBSA, MEDA, MSD, Nutraveris, Novartis, Pfizer, Rottapharm, Servier, SMB and Theramex.

Zhao Chen

Mel and Enid Zuckerman College of Public Health
University of Arizona
Tuscon, AZ, USA

Dr Zhao Chen has disclosed that she has no relevant financial relationships.

Judy W.M. Cheng

Massachusetts College of Pharmacy and Health Sciences
Boston, MA, USA

Prof. Cheng has disclosed that she has no relevant financial relationships.

Constantin A. Dasanu, MD, PhD

Clinical Professor of Medicine
University of California in San Diego, CA, USA

Eisenhower Health, CA, USA

Dr Dasanu has disclosed that he has no relevant financial relationships.

Lisa E. Davis

Philadelphia College of Pharmacy
University of the Sciences in Philadelphia
Philadelphia, PA, USA

Dr Davis has disclosed that her spouse is an employee of GlaxoSmithKline.

Andrea De Vito

Unit of Infectious Diseases
Department of Medicine, Surgery and Pharmacy
University of SassariSassari
Italy

Dr De Vito has no conflcits to disclose.

Moses S. Elisaf, MD, FRSH, FASA

Professor of Medicine, School of Medicine
University of Ioannina
Ioannina, Greece

Prof. Elisaf reports personal fees from Astra Zeneca, grants and personal fees from MSD, personal fees from Pfizer, personal fees and non-financial support from Abbott, personal fees and non-financial support from Sanofi, non-financial support from Boehringer INGELHEIM, personal fees and non-financial support from Eli Lilly, non-financial support and other from GSL.

Justin Faden DO

Lewis Katz School of Medicine, Temple University
Philadelphia, Pennsylvania, USA 

Dr Faden disclosed receiving research support from BioXcel and being a non-paid consultant/advisor for Noven. 

Alex Z. Fu

Department of Oncology
Georgetown University Medical Center
Washington, DC, USA

Prof. Fu has disclosed that he is the recipient of research/grant funding from Novartis, Merck & Co. Inc and is a consultant/advisor to CHEORS, Intuitive Surgical.

Nigel H. Greig

Translational Gerontology Branch
National Institute on Aging
NIH, Baltimore, MD, USA

Dr Greig has disclosed that that he is a shareholder of diversified stocks as well as some selected pharmaceutical stocks (particularly Elan and Amylin).

Paul O. Gubbins

Associate Dean at MSU

UMKC School of Pharmacy at MSU
Springfield, MO, USA

Dr Gubbins has disclosed that he has no relevant financial relationships.

Stuart T. Haines

The University of Mississippi
Oxford, MS, USA

Dr Haines has disclosed that he has no relevant financial relationships.

Kwok Ming Ho

Department of Anesthesia & Intensive Care, The Chinese University of Hong Kong
Hong Kong SAR, China

Department of Internal Medicine, University of Western Australia
Perth, Western Australia 

Dr Ho has disclosed that he has no relevant financial relationships. 

Michael Iskedjian

President, PharmIdeas Research and Consulting Oakville, ON, Canada

Mr Iskedjian has disclosed that he is a consultant/advisor to Amgen Inc., Ipsen Pharma, Nestle Nutrition Institute, Pfizer Inc., Sanofi Pasteur, Sepracor and Vertex Pharmaceuticals; has invested in the past, and may continue to invest in, broad mutual funds which from time to time may hold stock in pharmaceutical companies; and is an employee of PharmIdeas Research and Consulting.

Moyez Jiwa

Melbourne Clinical School
University of Notre Dame
Victoria, Australia

Prof. Jiwa has disclosed that he has no relevant financial relationships.

Siegfried Kasper

Dept of General Psychiatry
Medical University of Vienna
Vienna, Austria

Prof. Kasper has disclosed that he is the recipient of sponsorship funding from AstraZeneca, Eli Lilly, Lundbeck, Bristol Myers Squibb, Sepracor, Servier, Novartis and Pfizer; is the recipient of research/grant funding from Eli Lilly, Lundbeck, Bristol-Myers Squibb, Sepracor, Servier, Novartis and Pfizer; is a consultant or advisor to Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Pfizer, Janssen Pharmaceutica, Sepracor, Servier, Pierre Fabre, Wyeth, Merck Sharpe & Dohme and Schwabe; and is a member of the speakers bureaus of Astra-Zeneca, Bristol-Myers Squibb, Eli Lilly, Lundbeck, Janssen Pharmaceuticals, Pierre Fabre, Organon, CSC, Servier, Pfizer and GlaxoSmithKline.

Niki Katsiki, MSc, PhD, MD, FRSPH

Second Propedeutic Department of Internal Medicine, Medical School
Aristotle University of Thessaloniki
Hippokration Hospital
Thessaloniki, Greece

Dr. Katsiki has disclosed that she has given talks and attended conferences sponsored by Astra-Zeneca, MSD, Novo-Nordisk, Angelini, Novartis, Pfizer, WinMedica and Libytec and also participated in trials sponsored by Amgen and Novartis.

Gerald L Klein MD

Adjunct Professor of Pharmacology, Brody School of Medicine, East Carolina University
North Carolina, USA;

Principal, MedSurgPi LLC
North Carolina, USA

Dr Klein has disclosed that MedSurgPi LLC is a consulting group that consults for CROs, Biotech and pharma. 

Peter Y. Liu

ANZAC Research Institute, Concord Repatriation General Hospital
University of Western Sydney
Concord, Australia

Dr Liu has disclosed that he is a recipient of research/grant funding from Bayer Schering Australia.

Bradley C. Martin, PharmD, PhD

Professor and Director of Pharmaceutical Evaluation and Policy
University of Arkansas Medical Sciences
Little Rock, AK, USA

Prof. Martin has disclosed that he is a consultant/advisor for Daiichi Sankyo.

Sebastiano Mercadante, MD

Anesthesia and Intensive Care Unit and Pain Relief and Palliative Care Unit
La Maddalena Cancer Center, Palliative Medicine
University of Palermo, Italy

Dr Mercadante has disclosed that he has no relevant financial relationships.

Godfrey Nyangadzayi Musuka

International Initiative for Impact Evaluation
New Delhi
India

Dr Musuka has disclosed that he has no relevant financial relationships.

Jadwiga Najib

Professor of Pharmacy Practice
Long Island University
Brooklyn, NY, USA

Clinical Pharmacist
Department of Pharmacy and Psychiatry
St Luke’s/Roosevelt Hospital Center
New York, NY, USA

Prof.Najib has disclosed that she has no relevant financial relationships.

Dr Anthony D. Ormerod MB, ChB, MRCP, FRCP(Edin), MD, FRCP(Lond)

University of Aberdeen, King’s College, Aberdeen City, Aberdeen, UK

Dr Ormerod disclosed that he is the recipient of sponsorship for meeting attendance by Janssen-Cilag; has received research/grant funding from Merck & Co, and Abbott; and has been a consultant to Amgen.

Panagiotis Petrou

Adjunct Facility, Pharmacoepidemiology-Pharmacovigilance, Pharmacy School, Department of Health Sciences, University of Nicosia
Nicosia, Cyprus 

Professor Petrou has disclosed that he has no relevant financial relationships. 

John Plevris, MD, DM, PhD, FRCPE, FEBGH

Consultant Physician and Senior Lecturer, Centre for Liver and Digestive Diseases, Royal Infirmary of Edinburgh
University of Edinburgh
Edinburgh, UK

Professor Plevris has disclosed that he has been a recipient of research/grant funding from Aquilant and has been on the advisory board of Dr Falk.

J. Mark Ruscin

SIU Edwardsville School of Pharmacy
Southern Illinois University
Edwardsville, IL, USA

Prof. Ruscin has disclosed that he has no relevant financial relationships.

Cynthia Sanoski

Jefferson School of Pharmacy
Philadelphia, PA, USA

Dr Sanoski has disclosed that she has no relevant financial relationships.

Michael Schachter, FRCP

Senior Lecturer and Honorary Consultant in Clinical Pharmacology
National Heart and Lung Institute, Imperial College London, St Marys Campus
London, UK

Terry L. Seaton

St Louis College of Pharmacy
St Louis, MO, USA

Dr Seaton has disclosed that he is consultant/advisor to Ciena Healthcare Pharmacy and Therapeutics Committee.

Leo P. Semes

Dept of Optometry
University of Alabama
Birmingham, AL, USA

Prof. Semes has disclosed that he is advisor to/Speakers’ Bureau for Alcon, Allergan, B&L, Genentech, Maculogix, OptoVue, Shire, Zeavision; Stock holder of HPO.

Dr Schachter has disclosed that he has no relevant financial relationships.

David Shavelle, MD

Keck School of Medicine, University of Southern California, Los Angeles, CA USA

Dr Shavelle has disclosed that he is the recipient of research/grant funding from CSK, St Jude Medical, Marquet, Inc., Merck & Co. Inc and is a consultant/advisor to sanofi-aventis US.

Lizheng Shi, PhD

Tulane University School of Public Health and Tropical Medicine, New Orleans, LA USA

Dr Shi has disclosed that he is the recipient of research/grant funding from Bristol Myers Squibb and has acted as a consultant/advisor to Cepheid Inc.

Gerard Stansby, MA, FRCS, MChir

Professor of Vascular Surgery and Honorary Consultant in Vascular Surgery
School of Surgical & Reproductive Sciences, Newcastle University
Newcastle, UK

Prof. Stansby has disclosed that he has no relevant financial relationship.

David M. Taylor

Chief Pharmacist, Maudsley Hospital
South London and Maudsley NHS Trust
London, UK

Prof. Taylor has disclosed that he is a recipient of grants or research funding from Janssen, Lundbeck and Sunovion; has received lecture fees from Janssen, Otsuka, Servier, Lundbeck and Sunovion.

Karen J. Tietze

Philadelphia College of Pharmacy
University of the Sciences in Philadelphia
Philadelphia, PA, USA

Dr Tietze has disclosed that she has no relevant financial relationships.

Justin A. Vale

St Mary’s Hospital
London, UK

Mr Vale has disclosed that he has no relevant financial relationships.

Timothy E. Welty

Kansas University Medical Center
Kansas City, KS, USA

Prof. Welty has disclosed that he is the recipient of research/grant funding from Pfizer Pharmaceuticals.

Anthony S. Wierzbicki, DPhil, DM, FRCPath

Consultant in Metabolic Medicine and Chemical Pathology and Senior Lecturer
King’s, Guy’s & St. Thomas’ Medical School, St. Thomas’ Hospital Campus
London, UK

Dr Wierzbicki has disclosed that he is a site trial investigator for Amgen, Sanofi, Akcea, Merck Sharp & Dohome and Chiesi.

Masha Zhdanava 

Manager, Analysis Group
Montreal, Canada

M Zhdanava discloses that she is an employee of Analysis Group, a company that provides paid consulting services to pharmaceutical companies. She is currently actively involved in research for Johnson & Johnson Innovative Medicine (2023-2024).